JM Larrañaga
@xenux88
Followers
634
Following
3K
Media
16
Statuses
1K
Cardiologist. Inherited Cardiovascular Diseases Unit. Complexo Hospitalario Universitario A Coruña (CHUAC)
Corunna, Galicia
Joined July 2011
Impressive panel of world experts at the V Internacional workshop on #HypertrophicCardiomyopathy in A Coruña. Connie Benzina, Jodie Inglés, Philipe Charron, James Ware, Juan P Ochoa, Luis López, María Valverde
0
5
11
@rbarvil kicks off another amazing International Workshop on Cardiomyopathies Check the titles from the original program from 1993
1
3
3
Arrhythmias in recovery are usually not a good sign. This example here is in PKP2. Others have shown in other diseases. Is PKP2 distinct from DSP or is it an issue of sample size and selection https://t.co/qRoHKjH2JV
#cardiotwitter
1
4
16
pVO2 recovery by @GLewisCardiol - an important new measure on CPET. Derivation from an observational study at MGH, application in SEQUOIA-HCM shows how aficamten improved pVO2 recovery compared to placebo An excellent read here https://t.co/ajfJPVkBUO
#CardioTwitter
0
10
22
Leveraging clinical trial data, in 18,000 patients, cardiomyopathy variants, AF, and prognosis. Brilliant approach. Paper in @JACCJournals 1/2 https://t.co/DzpNH1YWOZ
#cardiotwitter #epeeps
1
13
31
🚨ANOTAR FECHA: 20 septiembre en CHUAC. Inscribiros y acercaros a participar en este encuentro. Este día nuestros corazones pueden dar voz a nuestras situaciones. 🙋Contamos con vuestra asistencia. #aemch #aemchipertrofica
0
5
4
👉Don’t miss the 2025 HCM A CORUÑA meeting!🇪🇸 💡 Latest updates on HCM, Amyloidosis & Fabry Disease with leading experts 🇪🇺🇺🇸🇦🇷🇦🇺🇬🇧 🗣️LATE-BREAKING NEWS: 🎥 VIRTUAL TICKETS NOW AVAILABLE!!! – join LIVE or ON DEMAND! 👉 Register today! https://t.co/oiMNsY6Byy
0
14
28
Uncovering SMAD6: a new link between cardiac conduction disorders and rare vascular diseases 👇🏻 Our colleague Almudena Amor, MD, PhD @almuamor2 has presented her study at #ESCCongress 🧬 If you would like to access the work you can request it here 👉 https://t.co/Y4l4h8BUZQ
0
5
9
Excellent talk by @fdefrutossemi at #ESCCongress 👏 While current ESC guidelines suggest genetics should not guide ICD implantation in HCM, he emphasized that not all variants behave the same. An important and timely debate —we’re glad to see this discussion kept alive! If
0
8
16
4
22
46
🚨 Live from #ESCCongress + now online in @CircAHA 🚨 https://t.co/KPsILAhJVT Honored to present our work on Intermediate-Effect Variants (IEVs) in HCM, selected for the Young Investigator Award. 🏆 60% of HCM cases G (-). Maybe we’ve been looking in the wrong place… 👇🧵
3
14
32
🚨 New @CircAHA #ESC2025 #SimPub alert! 🚨 HCM isn’t just driven by rare Mendelian mutations. This study highlights the role of intermediate-effect variants (IEVs)—variants with moderate effect & low penetrance—in shaping disease expression. #HCM
https://t.co/uEqW1ZmrDb
ahajournals.org
BACKGROUND: Hypertrophic cardiomyopathy (HCM) is a genetically heterogeneous disorder linked primarily to rare variants in sarcomeric genes, although recently certain nonsarcomeric genes have emerged...
2
12
24
Titin-related familial dilated cardiomyopathy: factors associated with disease onset https://t.co/WX2v4ySAyw
academic.oup.com
AbstractBackground and Aims. Truncating variants in the TTN gene (TTNtv) are the most common genetic cause of dilated cardiomyopathy (DCM) but also occur a
1
4
10
Nuestro último análisis del registro AMIGAL publicado en @EJIM_journal apoya la utilidad pronóstica de la determinación basal de prealbúmina sérica en pacientes con AC-ATTR @eduardo_barge @INESGOMEZ71 @MG_Crespo_Leiro @M_Lopez_Perez
https://t.co/OHiFJ2a7m4
0
5
10
TP-fusion at peak exercise: A novel marker for the recognition of unsuspected long QT syndrome patients
academic.oup.com
AbstractAims. The frequent occurrence of sudden death as the sentinel event in the long QT syndrome (LQTS) forces the search for still asymptomatic patient
0
1
8
Major arrhythmias in non-dilated left ventricular cardiomyopathy: a novel prediction score https://t.co/eCZz2IeFX2
academic.oup.com
AbstractBackground and Aims. The prediction of the first major arrhythmic event (MAE) is still an unmet need in the recently defined scenario of non-dilate
0
10
26
Flecainide use had a favorable safety profile and was associated with a significant reduction in arrhythmic burden in patients with ARVC, irrespective of the underlying genotype or LV involvement. https://t.co/tJBMMQTM3y
#JACCCEP #EPeeps #cardiomyopathy
1
98
256
Our paper just published! @NatRevCardiol We explore how precision medicine is transforming the treatment of cardiomyopathies — from genetics to targeted therapies. Precision medicine in cardiomyopathy is a reality! https://t.co/ElTVa6jbvZ
1
14
60